Objective. The most cost-effective dosing regimen for rituximab treatment in RA is currently unknown. The objective of this study is to determine whether low rituximab serum levels are associated with progression of structural damage in RA patients.
Introduction
Treatment with rituximab reduces disease activity in patients with RA. In parallel, rituximab is protective against progression of joint destruction in most patients, even in the absence of a clinical response [14] . However, a subset of patients still has progression of structural damage despite rituximab treatment [3, 5] .
In the IMAGE trial, treatment with a relatively low dosage of 2 Â 500 mg rituximab in 2 weeks time induced a similar decrease in disease activity compared with the regular treatment with 2 Â 1000 mg rituximab. However, treatment with 2 Â 1000 mg rituximab induced more effective inhibition of joint destruction compared with 2 Â 500 mg rituximab in the first 24 weeks post-treatment [4] . These data suggest that rituximab may have a different dosage effect for inhibition of erosion formation and disease activity.
Previously we found that rituximab levels after administration of 2 Â 1000 mg rituximab differ markedly between RA patients [6] . Conceivably, low rituximab levels after 2 Â 1000 mg rituximab may be related to less effective inhibition of progressive joint damage. If confirmed, this would strengthen the rationale for treatment with a high vs a low dosage of rituximab. Therefore we analysed whether low rituximab serum levels are associated with progression of structural damage in three cohorts of RA patients starting rituximab treatment.
Patients and methods

Patients
Patients were included from three independent prospective cohort studies of the response to rituximab treatment in RA that were reported previously [710] . All patients had active RA [DAS evaluated in 28 joints (DAS28) 53.2]. The study was approved by the Medical Ethics Committee of the Academic Medical Center, University of Amsterdam; all patients gave written informed consent obtained according to the Declaration of Helsinki.
Study design
Patients were treated with two infusions of 1000 mg of rituximab (days 1 and 15). Pre-medication with methylprednisolone was omitted in the Academic Medical Center/University of Amsterdam (AMC) cohort [9] . In all cohorts the DAS28 was obtained at baseline and after 24 weeks. Patients of the Leiden University Medical Center (LUMC) cohort were in all cases re-treated with rituximab after 6 months (fixed re-treatment), whereas patients of the AMC and University Medical Centre, Utrecht (UMCU) cohort were only re-treated when their DAS28 score was 53.2 at least 6 months after initiation of treatment (on-demand re-treatment). We included patients in this analysis only if radiographs obtained before and 1 year after treatment were available and when serum was available for measurement of at least one post-treatment level of rituximab.
Measurement of rituximab levels
Rituximab levels, measured after 4, 12 and 24 weeks (LUMC and UMCU) or 4, 16 and 24 weeks (AMC), were determined by sandwich ELISA. In short, anti-rituximab antibodies were generated in rabbits by immunization with rituximab F(ab)2. After purification of IgG with protein Asepharose, reactivity against human IgG was removed by passage over a sepharoseIVIG column. IVIG is a therapeutic i.v. IgG preparation prepared from more than 1000 blood donors. The antibodies that did not bind to the column were not reactive with serum IgG but strongly recognized rituximab. They were used for coating the ELISA plate and, after biotinylation, also as conjugate. The detection limit of the assay is 0.08 ng/ml. Because sera are tested at 1:10 dilution or higher, the detection limit in serum is 0.8 ng/ml.
Radiographic assessments
Radiographs of the hands and feet were obtained at baseline and 1 year after the initiation of rituximab treatment. The same observer, who was blinded to radiograph sequence, evaluated paired radiographs using the Sharpvan der Heijde scoring method (SHS), which consists of the joint space narrowing score and erosion score (range 0448) [11] . Patients were divided into progressors vs nonprogressors based on the change from baseline in SHS after 1 year using three different definitions of progression: an increase in SHS of 51 point, 53 points or 55 points.
Statistical analysis
Differences in rituximab levels between progressors and non-progressors were compared using the MannWhitney U test for nonparametric data. The Pearson's correlation coefficient was used to assess correlations. All statistical analyses were performed with SPSS 17.0 software (SPSS, Chicago, IL, USA).
Results
Patient characteristics
Results on the radiographic progression and at least one post-treatment rituximab level were available for 24, 25 and 13 patients from the different centres. Baseline clinical characteristics and clinical response are shown in , although interquartile ranges are large and the differences are not statistically significant (week 4: P = 0.083; week 12/16: P = 0.131; week 24: P = 0.651). This difference might be explained by chance, consistent with previous literature [12] .
No difference in rituximab serum levels between progressors and non-progressors First, we pooled the data of the three cohorts. Fig. 1A shows the rituximab levels at 4, 12 or 16 and 24 weeks after the start of treatment for progressors and non-progressors using the three different cut-offs. Based on an increase in SHS of 51 point, 53 points or 55 points, we found 37 (60%), 33 (53%) and 23 (37%) progressors, respectively. We did not find any (trend towards a) difference in levels of rituximab between progressors and nonprogressors at any time point (Fig. 1A) . Using the cut-off of an increase in SHS of 53 points, the rituximab levels between progressors and non-progressors at week 4 were 126 (72181), n = 29, and 128 (102160), n = 27, respectively (P = 0.74). In addition, the pooled levels of week 12 of the two cohorts were 6.0 (3.118), n = 29, and 8.2 (0.316.5), n = 9, respectively (P = 0.68).
Next we compared the rituximab levels between progressors and non-progressors of the three cohorts separately using the cut-off of an increase in SHS of 53 points. On week 4 we did not find any differences in the separate cohorts. Of note, on week 12 the UMCU cohort showed significantly higher rituximab levels in the progressor group [8.7 (3. tended to be lower in the progressor group [5.9 (2.415.7), n = 21, vs 16.5 (10.823.0), n = 4; P = 0.08). Finally, we did not observe any difference in serum rituximab levels between progressors and non-progressors at week 16 in the AMC cohort [1.8 (0.322.7), n = 4, and 3.5 (1.38.0), n = 19, respectively; P = 0.42).
No correlation between change in structural damage and rituximab serum levels
We also analysed the continuous data on the change in SHS score after 1 year. We did not find any significant correlation with the rituximab serum levels at different time points (Fig. 1B) . In addition, the three seronegative patients were randomly distributed throughout the dot plot.
No difference in progression of structural damage between re-treated and non-re-treated patients
Because different re-treatment regimens were followed in the different cohorts (fixed re-treatment vs on-demand re-treatment), some patients received re-treatment with rituximab in the first year after initiation of treatment and some did not. However, we did not find a (trend towards a) difference in progression of structural damage between the re-treated (n = 45) and non-re-treated patients (n = 17; P = 0.26; data not shown).
Discussion
The results of this prospective cohort study show that there is no relationship between rituximab serum levels measured 4 or 12 or 16 weeks after initiation of treatment and progression of structural damage, based on three independent cohorts of RA patients. The data do not support the continued use of higher dosages of rituximab to inhibit progression of joint destruction.
In a previous study that we performed on the relationship between rituximab serum levels on the one hand and B cell depletion and clinical response on the other, we observed that rituximab levels are highly variable between patients, but that low rituximab serum levels cannot explain the persistence of synovial B cells or clinical non-response [6] . The lowest rituximab levels were found in patients with anti-rituximab antibodies (ARAs) [6] . In the current study it was not possible to reliably compare progression of destruction between patients with and without ARAs, as the proportion of patients forming ARAs after the first treatment course was low (9%) and for only half of those patients were paired radiographs available. Nonetheless, the data show that low rituximab levels are not related to progression of structural damage, suggesting that treatment with higher dosages than 2 Â 1000 mg rituximab is unlikely to be more effective in protecting against progressive joint destruction. This contrasts with rituximab treatment in non-Hodgkin lymphoma, where low rituximab levels are related to decreased response to therapy [13, 14] . In contrast, it might perhaps even be possible to lower the dose of rituximab re-treatment after a starting dose of 2 Â 1000 mg. Recently 2 Â 1000 mg and 2 Â 500 mg were compared side by side in early active RA patients. Only initial treatment with 2 Â 1000 mg rituximab resulted in statistically significant protection against progression of structural damage at 1 year, whereas 2 Â 500 mg and 2 Â 1000 mg resulted in comparable clinical efficacy. Exploratory analysis suggested that re-treatment with 2 Â 500 mg rituximab after 24 weeks might also be protective in terms of inhibition of structural damage [4] . Future research is needed to address this question and to study if this also holds true for patients with established, late-stage RA.
This study has some limitations. First, the study is relatively small. Second, the degree of progression that can be reliably detected above the measurement error of the SHS is best determined by the smallest detectable change (SDC), which is usually around 3 [15] . Therefore we chose the cut-off value of an increase in SHS of 3 points to study the rituximab levels in the three separate cohorts. We could not calculate the SDC for this study because the radiographs were scored by one observer and the SDC is calculated with repeated scores of two observers. Of note, the cut-off values of 1 and 5 points also did not show a difference in rituximab serum levels.
The only notable initial difference between the three cohorts is the concomitant MTX use, which was lower in the UMCU cohort. However, this did not influence the rituximab serum levels after treatment. Taken together, our data do not support the use of dosages higher than 2 Â 1000 mg rituximab in order to more effectively inhibit progression of joint destruction.
Rheumatology key messages
. Low rituximab levels are not related to progression of structural damage in RA patients. . Dosages of rituximab higher than 2 Â 1000 mg are unlikely to inhibit progression of joint destruction more effectively in RA patients.
